主页 > 医药生命 >
【medical-news】循环中微型核糖核酸(microRNA)有助于
In order to cut the morbidity and mortality of cancer worldwide, there is a need for better methods of detecting epithelial malignancies, senior author Dr. Muneesh Tewari, from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues note.
MicroRNAs, which are often dysregulated in cancer, appear to be useful tissue-based markers for classifying cancer and predicting outcomes. The present findings, which appear in the Proceedings of the National Academy of Sciences for July 29, suggest that microRNAs also exist in blood in a stable form that is resistant to endogenous RNase.
Testing in mice grafted with human prostate cancer, the researchers found that microRNAs from the malignancy could be readily detected in plasma. By looking for these markers, the team was readily able to distinguish mice with cancer from their healthy counterparts.
Taking this one step further, Dr. Tewari's team tested for serum levels of miR-141, a known prostate cancer microRNA, in the serum of men with and without the malignancy. Once again, the test readily distinguished the two groups.
"Our results establish the measurement of tumor-derived microRNAs in serum or plasma as an important approach for the blood-based detection of human cancer," the researchers conclude.
Proc Natl Acad Sci USA 2008;105:10513-10518. 本人已认领该篇文章，48小时候如果未交出请其他战友自动认领。 NEW YORK (Reuters Health) Jul 28 - New research suggests that measurement of tumor-derived microRNAs in blood may be a useful means of detecting cancer.
纽约（路透通讯社 健康） 7月28日 一项新的研究表明血液中肿瘤来源的microRNA的测量可能是一种有用的检测癌症的手段。
In order to cut the morbidity and mortality of cancer worldwide, there is a need for better methods of detecting epithelial malignancies, senior author Dr. Muneesh Tewari, from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues note.
为了减少世界范围内癌症的发病率和死亡率，需要一种更好的方法来检测上皮恶性肿瘤。来自于西雅图Fred Hutchinson 癌症研究中心的资深学者Muneesh Tewari及其同事这样认为。
MicroRNAs, which are often dysregulated in cancer, appear to be useful tissue-based markers for classifying cancer and predicting outcomes. The present findings, which appear in the Proceedings of the National Academy of Sciences for July 29, suggest that microRNAs also exist in blood in a stable form that is resistant to endogenous RNase.
MicroRNAs在癌中常常失调，看起来可以做为基于组织的用于癌症分类和预后的标志。现在的发现表明，microRNAs也已一种稳定的形式存在于血液中，对RNA酶有抵抗力。这发表在PNAS的7月29日杂志上。
Testing in mice grafted with human prostate cancer, the researchers found that microRNAs from the malignancy could be readily detected in plasma. By looking for these markers, the team was readily able to distinguish mice with cancer from their healthy counterparts.
用移植了人前列腺癌的小鼠进行试验，研究人员发现恶性肿瘤中来源的microRNAs可以很容易的从血浆中检测到。通过寻找这些标志分子，这个团队已经能够把患癌症的小鼠从健康对照鼠中区分开来。
Taking this one step further, Dr. Tewari's team tested for serum levels of miR-141, a known prostate cancer microRNA, in the serum of men with and without the malignancy. Once again, the test readily distinguished the two groups.
通过进一步的研究，Tewari's团队检测了患有恶性前列腺癌和不携带患者血清中miR-141的水平，miR-141是已知的前列腺癌miRNA。同样，他们很容易把患者区分出来。 纽约（路透通讯社 健康） 7月28日 一项新的研究表明血液中肿瘤来源的microRNA的测量可能是一种有用的检测癌症的手段。
为了减少世界范围内癌症的发病率和死亡率，需要一种更好的方法来检测上皮恶性肿瘤。来自于西雅图Fred Hutchinson 癌症研究中心的资深学者Muneesh Tewari及其同事这样认为。
MicroRNAs在癌中常常失调，看起来可以做为基于组织的用于癌症分类和预后的标志。现在的发现表明，microRNAs也已一种稳定的形式存在于血液中，对RNA酶有抵抗力。这发表在PNAS的7月29日杂志上。
用移植了人前列腺癌的小鼠进行试验，研究人员发现恶性肿瘤中来源的microRNAs可以很容易的从血浆中检测到。通过寻找这些标志分子，这个团队已经能够把患癌症的小鼠从健康对照鼠中区分开来。
通过进一步的研究，Tewari's团队检测了患有恶性前列腺癌和不携带患者血清中miR-141的水平，miR-141是已知的前列腺癌miRNA。同样，他们很容易把患者区分出来。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-07 17:14
医学,生命科学网